期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 79, 期 6, 页码 724-726出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-217407
关键词
-
类别
资金
- Actelion
- CSL Behring
- Eli Lilly
- Inventiva
- Roche
- Sanofi
- Abbvie
- Celltrion
- Sanofi-Genzyme
- SOBI
- GlaxoSmithKline
- Corbus, Acceleron
- Competitive Drug Development International Ltd
- Ergonex
- Bayer
- Boehringer Ingelheim
- Pfizer
- Regeneron
- Gilead and Seattle Genetics
- DEF
- Corbus, Galapagos GSK
- Mitsubishi
- Boehringer-Ingelheim
- Genentech/Roche
- Actelion Pharmaceuticals
- Chugai
- Eisai
- Mochida
- Novartis
- Ono
- Reata
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据